PITTSBURGH, July 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq:
MYL) today announced that the U.S. District Court for the District
of New Jersey granted its motion
for a temporary restraining order against Apotex Inc. and Apotex
Corporation in litigation relating to Paroxetine CR, the authorized
generic of GlaxoSmithKline's Paxil® CR. The
District Court ordered Apotex to immediately discontinue all sales
and supply of Paroxetine CR. Mylan previously obtained an order
enjoining GlaxoSmithKline from supplying Paroxetine CR to
Apotex.
In addition, the District Court ordered Apotex to immediately
recall all product from its direct customers that was shipped since
the injunction was entered on July
16, 2014.
Mylan has an exclusive license to an Orange Book patent
pertaining to Paxil CR which expires in July
2016, with pediatric exclusivity extending until
Jan. 19, 2017. Mylan further believes
that it is the only company to have filed an abbreviated new drug
application for generic Paxil CR that contains a paragraph IV
certification.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. But don't take our word for
it. See for yourself. See inside. mylan.com
Logo - http://photos.prnewswire.com/prnh/20140423/77793
SOURCE Mylan Inc.